However, in the absence of an in-depth understanding of how the different p53 isoforms contribute to potentially more aggressive cancer (TAp53 and p53β) and a lack of therapies that can directly target the various p53 isoforms, their role in melanoma needs to be considered conservatively and future studies should aim to establish the isoforms’ contribution to pathophysiology through in vitro knockout and overexpression studies, and the use of animal models. This evidence concerns the gene TP53 and melanoma.